Thomas M. Habermann, M.D.
Professor of Medicine, Mayo Clinic College of Medicine
Consultant, Division of Hematology
Involved in the field of lymphoma for 32 years at Mayo Clinic

Locations:

• Geffen Auditorium (Live)
• Broadcast to SMH Alfred M-459 and MA 17-64
• Mayo Clinic Health System in Waycross (Video Conference)

Lunch available outside Geffen Auditorium and SMH Alfred M-459 on a first come, first serve basis

Learning Objectives:

• Describe the natural history, outcomes, and complications of treated hodgkin lymphoma
• Describe the standard treatment modalities and approaches for the management of Hodgkin lymphoma
• Describe the new biologic approaches in the management of Hodgkin lymphoma
• Recognize contributions of the Mayo Clinic Lymphoma Group to the field of Hodgkin lymphoma since 1986

Financial Disclosure:

• None

Off Label/Investigational Uses:

• Novartis, Kite - Car-T cells, Everolimus
• Bristol-Meyers Squibb - Nivolumab
• Merck - Pembrulizumab
• Genentech, Roche - Rituximab
• Rituximab nanoparticle
• Tipirarnib

Mayo Clinic College of Medicine and Science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.